The E3 ligase tripartite motif-containing protein 16 (TRIM16) was demonstrated to act as a suppressor of pathological cardiac hypertrophy (relieve peroxiredoxin 1 (PRDX1) phosphorylation and oxidative stress) and indicated that targeting the TRIM16–PRDX1 axis is a promising therapeutic strategy for hypertrophy-related HF [95]. Here, TRIM16 is linked to cardiac hypertrophy.